Objective. The relevance of the Th17 pathway in primary SS (pSS) is unclear. Published studies have relied on restimulating circulating CD161 + T cells in vitro for quantitation of IL-17producing cells. While CD161 marks all IL-17 + T cells, it is also expressed by other Th subsets. The aim of this study was to directly analyse retinoic acid receptorrelated orphan nuclear receptor (ROR)Àg expressing and non-expressing subsets of CD161 + T cells to determine the relevance of the Th17 pathway in pSS.
Results. While the frequencies of both RORg + and RORg À subsets of CD161 + CD4 + T cells were increased in peripheral blood from pSS patients, the increase in the RORg + subset positively correlated with humoral manifestations of the disease (anti-SSA/SSB autoantibodies and hypergammaglobulinaemia), but not with disease activity, and vice versa for the RORg À subset. An increased frequency of HLA-DR + CD161 + CD4 + T cells was observed in labial salivary gland biopsies from pSS patients, suggesting chronic activation of CD161 + CD4
+ T cells in the target tissue of the disease.
Conclusion. In addition to pointing to CD161 as a marker of a pathogenic subset of CD4 + T cells in pSS patients, our data indicate that even though the RORg + (Th17) CD161 + subset might contribute to humoral manifestations of the disease, the RORg À (non-Th17) CD161 + subset is the one associated with disease activity in pSS patients.
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Rheumatology key messages
. Relevance of the Th17 pathway in primary SS was determined by direct analysis of RORg + CD161 + T cells.
. Selective presence of an activated population of CD161 + CD4 + T cells in target tissues of primary SS patients was observed.
Introduction
Primary SS (pSS) is a chronic autoimmune disease characterized by dysfunctional salivary and lacrimal glands, accompanied by multi-organ involvement in 75% of the patients [1] . Histologically, the disease is characterized by lymphocytic infiltration of the exocrine glands, with predominantly CD4 + T cells and plasma cells, but also CD8 + T cells [2À4] . Th1 cells are thought to be the predominant CD4 + T cell subset infiltrating human biopsies [5, 6] , even though cytokine profiling identified secreting patterns that are compatible with other effector T cell subsets [3, 4, 7] . Accordingly, markers of Th17 cells were detected in pSS biopsies [8, 9] , but the relative importance of the Th17 pathway in pSS pathogenesis remains unclear. Th17 cells, a subset of the Th lineage, are key contributors to several inflammatory pathologies in humans, such as psoriasis, IBD and AS [1014] . The retinoic acid receptorrelated orphan nuclear receptor (ROR)g (gt), controls a pro-inflammatory gene expression program in Th17 cells that has been implicated in the pathogenesis of several human immune-mediated diseases, including pSS [15, 16] . In mice, the observation that transgenic expression of RORgt in the T cell compartment leads to the spontaneous development of severe pSS-like manifestations points to a role for RORg in pSS [17] . Detection of IL-17 primarily, as well as of other cytokines in the pathway such as IL-23 and IL-6, has also been described in salivary glands and sera from several mouse models of pSS [18] . Mounting evidence in humans also supports this hypothesis because Th17-related cytokines have been detected in serum, tears and saliva of pSS patients [8, 9, 18, 19] . However, no association between IL-17/Th17 cells and disease severity or specific extraglandular clinical manifestations has been reported (reviewed in [20] ) and a direct characterization of RORg-expressing T cells has not yet been performed in pSS patients.
In 
Flow cytometry analysis
Peripheral blood mononuclear cells (PBMCs) were isolated from peripheral blood as described previously [2] . Approximately 1Â 10 6 PBMCs were stained with fluorescent-labelled antibodies for detection by flow cytometry. For intracellular detection of RORg, Cytoperm/Cytofix reagent was used according to the manufacturer's instructions (BD Biosciences, San Jose, CA, USA). BD LSRII was used for data acquisition, and the data were analyzed with FloJo software (Tree Star, Inc.).
Antibodies/reagents
CD4-V450 (BD, clone: RPA-T4), CD8-APC-H7 (BD, clone: SK1), CD3-BUV737 (BD, clone: UCHT1), CCR6-PerCPCy5.5 (Biolegend, Clone: G034E3), RORg-Alexa Fluor 647 (BD, Clone: Q21-559), CD45RA-A700 (BD, clone: H100) and CD161-PE (Biolegend, HP-3G10) were used. For single cell suspensions from LSG biopsies and CyTOF analysis, refer to [2] for detailed protocol.
Statistical analysis
Data are expressed as mean (S.D.). Data were analysed using Prism software (GraphPad Prism Software Inc., USA), the MannWhitney U test and Spearman's rank correlation. P < 0.05 was considered statistically significant. 3.6 (1.5%) vs 2.4 (1.2%), respectively]. To rule out the possibility that this increase could result from variations in other cell lineages, we also quantified the frequency of these subsets within the CD4 + T cell lineage (Fig. 1D ). This analysis showed that the frequency of total CD161 + cells were increased by 2-fold in pSS [11.9 (5.5%) vs 6 (3.1%), positively correlated (r=0.4, P < 0.05) with serum IgG levels in pSS patients (Fig. 3B, middle) . In contrast, the frequency of the RORg À subset (Fig. 3A and B, right) did not correlate with anti-SSA/anti-SSB antibody positivity or serum IgG levels, even though there was a significant increase in the frequency of this subset in anti-SSA + pa- Next, we tested the potential relationships between CD161 + T cell subsets and disease activity using the EULAR SS disease activity index (ESSDAI) score [37] . As shown in Fig. 4A (left) , there was a significant increase in the frequency of CD161 + CD4 + T cells (by 2-fold on average, P = 0.003) in pSS patients with at least one domain of ESSDAI activity (ESSDAI>1), but not in patients with more muted forms of the disease (ESSDAI=0). The frequency of CD161 + CD4 + T cells also correlated with individual . Consistent with these data, the frequency of this population showed a clear correlation with individual disease activity scores ( Fig. 4B, right ; r=0.6, P = 0.0005).
Results

Both
P < 0.0001
FIG. 1 Comparison of frequencies of circulating CD4 + T cells expressing CD161 and RORg between primary SS and nonprimary SS patients (A) Representative flow cytometric plots of PBMCs from pSS (A) and non-pSS (B) patients gated on CD3
+ CD4 + cells showing CD161 (top) and RORg (bottom) expression. The population, positive for CD161 and RORg expression, is gated based on the negative (FMO) control, which is indicated as a grey-filled histogram in the overlays. The percentage age of cells in each gate is indicated above the bar in the histogram plots (refer to Supplementary Fig. S1 all pSS and non-pSS samples analysed. The bars indicate the median values. All error bars denote ±S.D. *P < 0.05; **P < 0.005; ***P < 0.0005; ****P < 0.00005; NS = not significant. (P > 0.05). P-values were determined by the MannWhitney U-test. FMO: fluorescence minus one; PBMC: peripheral blood mononuclear cell; pSS: primary SS.
In comparison, the RORg + subset (Fig. 4A, middle) was most significantly increased in the group of patients with low disease activity [4 (3.2%), ESSDAI=14], while it showed only a small increase in patients with high disease activity [3.4 (1.1%)] in comparison with patients with inactive disease [3 (2.5%)] or non-pSS subjects [1.9 (1.4%)]. As predicted, this population showed no correlation with individual disease activity scores when treated as a continuous variable (Fig. 4B, middle) .
Increased frequency of activated HLA-DR + CD161 + CD4 + T cells in the salivary glands from pSS patients with focus score >1
Because cellular variations in blood only indirectly inform on disease pathogenesis, we also analysed labial salivary gland (LSG) biopsies from subjects undergoing a diagnostic biopsy for pSS. The expression of Klrb1 (encoding CD161) was previously shown to be significantly . Encouraged by this strong upregulation at the mRNA level, we used singlecell suspensions from human LSG biopsies and included HLA-DR and CD161 antibodies in a cytometry by time-offlight immuno-phenotyping panel that was used in the context of a broader immunophenotyping study published recently [2] . A detailed gating strategy has been outlined in Supplementary Fig. S3 , available at Rheumatology Online. This analysis revealed that most of the glandular CD8 + T cells that showed an activated HLA-DR + phenotype in pSS biopsies were CD161 (Fig. 5) . In contrast, even though the overall proportion of HLA-DR + CD4 T cells was not significantly changed in pSS patients with a focus score >1 (see detailed analysis in [2] ), a unique population of HLA-DR + CD161 + cells was increased in these patients (P = 0.002), contributing to up to a third of the activated CD4 + T cells in the biopsy tissue (Fig. 5) .
Discussion
There is compelling evidence that the RORg/Th17 pathway is an attractive target for the treatment of several autoimmune and inflammatory diseases [1013, 38] . The evidence supporting the importance of this pathway in human pSS, however, has been confounding for several reasons. First, a correlation between the Th17 pathway and disease activity is still lacking in the literature [20] . Second, researchers tend to focus on CD161-expressing CD4 + T cells in peripheral blood and rely on the restimulation of the cells in vitro to evaluate the activity of the Th17 pathway in patients, as in the recently published paper by Li et al. [25, 38, 39] and other publications. However, the CD161 marker is not exclusively associated with a Th17 phenotype. Only 2030% of CD161 + CD4 + and 7080% of CD161 + CD8 + memory T cells express RORg in healthy donor PBMCs [23, 30] , an observation that we confirmed here in both non-pSS and pSS subjects. Therefore, using CD161 solely as a Th17 marker does not allow for accurate quantification of Th17-committed cells.
In this study, we analysed both the expression of CD161 and RORg in a well-stratified cohort of pSS patients. Our focus score of >1. Since this population was not detectable in control subjects, it is suggestive of a pathogenic role in pSS. This conclusion is further supported by transcriptomic analyses of the human target tissue, which showed clear upregulation of klrb1 gene expression in biopsies from pSS patients [29] . Future studies will determine whether the pathogenicity of this population in the target tissue is associated with a Th17 or other T effector pathways, but our cellular phenotypic data on peripheral blood indicate that Th17 might not be the dominant pathogenic pathway associated with the CD161 + phenotype. 
